ZINBRYTA, which was recently approved by the U.S. Food and Drug Administration (FDA), was developed to treat relapsing types of multiple sclerosis (MS) in adult patients. Read More »
Managing and monitoring the increasingly high cost of speciality drugs will be a key challenge to control insurance prices over the next two years, say employers and third party payers. Read More »
Second trial of cariprazine in treatment of MDD did not show significant changes versus placebo. Read More »
Continues expanding access to the opioid overdose reversal drug naloxone in all CVS Pharmacies. Read More »
Results of first annual general meeting of the health and wellness company announced. Read More »
Fexapotide produces positive results in two long-term Phase III clinical trials. Read More »
The American Pharmacists Association (APhA) Foundation recently announced the recipients of its 2016 Pinnacle Awards. Read More »
Cynapses Therapeutics Inc., a pharmaceutical company that specializes in the central nervous system (CNS), this week announced the completion of its Data Safety and Monitoring Board (DSMB) review of the safety data from its Phase III CTH-300 and CTH-301 clinical trials. Read More »
Vital Therapies Inc. recently announced the appointment of Faheem Hasnain to its board of directors Read More »
Imprimis Pharmaceuticals Inc., which uses its Branded Compounding business model to make drugs more cost-efficient, recently announced the appointment of Clayton Edwards as the SVP of Operations, Eric Rice as the VP of Client Relations, Pramod Sharma as the VP of Quality and Sanjay Samudre as its Director of Manufacturing. Read More »
CVS Health announced today that naloxone, an opioid overdose-reversal medication, is now available without a prescription in its Colorado locations after CVS came to terms on a standing order with physicians across the state. Read More »
Nearly half of all Americans receive a flu shot every year; availability and no appointment necessary are determining factors. Read More »
CVS Health and the CVS Health Foundation will donate $100,000 in cash and in-kind support to organizations that are helping the flooding victims of central Louisiana by providing relief efforts. Read More »
EnteroMedics has chosen Gary Blackford to join its board of directors, replacing Anthony Jansz, who will be stepping down from his board position. Read More »
Trial evaluating Sollpura for treatment of exocrine pancreatic insufficiency in cystic fibrosis patients. Read More »
Pulmatrix this week announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug status for PUR1900, the company’s inhaled drug designed to treat pulmonary fungal infections in patients with cystic fibrosis (CF). Read More »
Avion Pharmaceuticals this week announced that it has fortified its partnership with Gnosis S.P.A. by agreeing to make Quatrefolic part of its Prenate prescription prenatal vitamin portfolio. Read More »
Phase III trial produces positive results in treating primary biliary cholangitis with Ocaliva. Read More »
Juniper Pharmaceuticals Inc. announced last week its Phase IIb clinical trial for COL-1077, which was recently completed, did not meet either its primary or secondary goals. Read More »
.jpg)
Supernus Pharmaceuticals Inc. recently reported that its Supplemental New Drug Application (sNDA) that requested an expansion to the label of Trokendi XR to include prophylaxis for migraine headaches in adults has been granted tentative approval by the U.S. Food and Drug Administration (FDA). Read More »
Alerts Sign-up
